Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. develops regenerative cellular therapies centered on laromestrocel, also known as Lomecel-B, a proprietary allogeneic investigational cell therapy. The company’s clinical programs address hypoplastic left heart syndrome, Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging-related frailty.
Recurring news for LGVN covers clinical-trial safety reviews, FDA interactions and designations, intellectual-property updates for mesenchymal stem cell methods, financial results, private placements, and Nasdaq-related corporate matters. Updates often focus on the ELPIS II HLHS program, laromestrocel regulatory strategy, and financing used to support clinical development.
Longeveron (NASDAQ: LGVN) reported new post‑hoc analyses from its CLEAR-MIND Phase 2a trial of stem cell therapy laromestrocel in mild Alzheimer’s disease, presented at the 2026 Alzheimer’s Association International Conference (AAIC) in London.
According to Longeveron, free water MRI data suggested laromestrocel stabilized brain inflammation in key gray and white matter regions versus placebo, with trends toward reduced free water in structures such as the fornix, sagittal stratum, and uncinate fasciculus, and correlations with greater brain volume and improved cognitive and quality-of-life scores. Blood biomarker analyses showed reduced neurogranin levels and increased IL-13 versus placebo in certain dosing groups. Longeveron noted that laromestrocel holds FDA Regenerative Medicine Advanced Therapy and Fast Track designations for mild Alzheimer’s disease, and the company has aligned with the FDA on a Phase 3 study design.
Longeveron (NASDAQ: LGVN) appointed Marie Washburn as Senior Vice President and Chief Financial Officer, effective July 13, 2026. She becomes principal financial and accounting officer, succeeding Lisa Locklear.
Washburn brings 20+ years of pharma/biotech finance experience. The company is focused on Phase 2b laromestrocel trial top-line results in HLHS, anticipated in the third quarter of 2026.
Longeveron (NASDAQ: LGVN)/b) announced that additional Phase 2a clinical data analysis of its stem cell therapy in mild Alzheimer’s disease was accepted for a poster presentation at the 2026 Alzheimer’s Association International Conference (AAIC) in London, July 12-15, 2026.
The poster, titled “Laromestrocel in Mild Alzheimer’s Disease: Additional Phase 2a Clinical Data Analysis,” will be presented Monday, July 13, 2026, 7:30am–4:15pm BST. According to Longeveron, prior CLEAR MIND Phase 2a results supporting laromestrocel’s therapeutic potential were published in Nature Medicine in March 2025.
Longeveron (NASDAQ: LGVN), a clinical-stage biotech developing cellular therapies for rare pediatric and aging-related conditions, has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA).
SME designation provides access to EMA scientific advice, protocol assistance, early regulatory dialogue, and reduced administrative fees, aiming to mitigate development delays. EMA data indicate SME marketing authorization success for human medicines reached 89% in 2020.
Longeveron (NASDAQ: LGVN) will present at the BIO International Convention 2026 in San Diego from June 22-25, 2026. The company’s corporate and laromestrocel (LOMECEL-B®) overview is scheduled for June 24 at 2:15pm PT in Theater 4.
Longeveron will highlight new and recently published data for stem cell therapy laromestrocel and pursue potential partnership and strategic opportunities across Hypoplastic Left Heart Syndrome, Alzheimer’s disease, Pediatric Dilated Cardiomyopathy and Aging-related Frailty programs, which it estimates represent multi-billion-dollar market opportunities.
Longeveron (NASDAQ: LGVN) outlined a refocused strategy centered on its stem cell therapy laromestrocel (Lomecel-B), prioritizing licensing partnerships and capital efficiency.
Key 2026 priorities include Phase 2b HLHS ELPIS II data in August, advancing pediatric cardiomyopathy and Alzheimer’s programs, and leveraging a March financing of up to approximately $30 million.
Longeveron (NASDAQ: LGVN) reported Q1 2026 revenue of $0.4 million, flat year over year, and a net loss of $4.7 million versus $5.0 million in Q1 2025. Cash and equivalents were $15.8 million, with runway into Q4 2026.
The company closed a private placement of up to $30 million, including $15 million initially funded, and targets August 2026 top-line Phase 2b ELPIS II results in hypoplastic left heart syndrome while pursuing partnerships across its HLHS, Alzheimer’s, pediatric dilated cardiomyopathy and aging-related frailty programs.
Longeveron (NASDAQ: LGVN) reported that an independent Data Monitoring Committee completed its final planned review of the fully enrolled Phase 2b ELPIS II trial of laromestrocel (Lomecel-B) for hypoplastic left heart syndrome (HLHS).
The DMC found no new safety concerns, recommended the study continue as designed, and top-line results are anticipated in August 2026. ELPIS II enrolled 40 pediatric patients at 12 centers and is conducted with NHLBI support. Prior ELPIS I data showed 100% transplant-free survival to age five in treated children. Laromestrocel holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS.
Longeveron (NASDAQ: LGVN) held a Type C meeting with the U.S. FDA; the Agency said right ventricle ejection fraction (RVEF) is not an appropriate primary endpoint for the ELPIS II Phase 2b trial for hypoplastic left heart syndrome. Top-line results are anticipated in August 2026. The FDA will not agree a new primary endpoint while the trial remains ongoing because of an interim NIH-mandated analysis, and therefore no longer describes ELPIS II as pivotal. The FDA said objective measures (all-cause mortality, transplant-free survival, cardiac transplantation, well-defined MACE) could be informative. Longeveron will submit a Sponsor Statistical Analysis Plan proposing a composite primary endpoint and remains optimistic about a possible BLA path after readout.
Longeveron (NASDAQ: LGVN) will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after U.S. market close. The company will host a conference call and webcast the same day at 4:30 p.m. ET.
Conference call number: 1.877.407.0789 with Conference ID 13759888. A replay will be available in the Events & Presentations section of the company website following the call.